Why Palatin Is Still A Buy
Palatin Technologies, Inc. (NYSE: PTN) spiked dramatically on Friday in response to Thursday's FDA approval of Sprout Pharmaceuticals' female sexual dysfunction drug, flibanserin.
Roth Capital analyst Joe Pantginis published a report on Friday predicting that the ruling would reduce regulatory overhangs blocking the approval of Palatin's own FSD drug, bremelanotide (BMT).
Many investors seemed to agree, as its share price jumped by as much as 50 percent Friday morning. Shares traded recently at $1.20, up $0.30 or 31 percent.
In a conversation with Benzinga, Pantginis chalked up the strong market reaction to surprise over the FDA ruling. He said investors may not have been expecting the flibanserin approval because of "the convoluted history that the drug has had with regulators." According to him, it had been turned down multiple times by the agency before Thursday's decision.
BMT vs. Flibanserin
Despite the strong market reaction, however, Pantginis sees Palatin as a Buy. According to him, Palatin and Sprout are the only two producers of a drug for female sexual dysfunction, and BMT has a sizable edge over flibanserin. Specifically, he said, BMT doesn't have any of the major dangerous side effects that may turn patients away from flibanserin.
Furthermore, he noted, Sprout's drug comes as a chronic daily use prescription while Palatin's version can be taken on demand.
Bullish on Biotech
In addition to his positive outlook on BMT, Pantginis thinks that Palatin could be boosted by a general upswing in the biotech industry. He said that big pharmaceutical players are sharply scaling back their research and development divisions, instead opting to look to smaller biotech companies to fill these R&D channels. A bulk of M&A activities between pharmaceutical corporations and biotech firms should bolster the industry, according to Pantginis.
Latest Ratings for PTN
|Jun 2015||Canaccord Genuity||Maintains||Buy|
|Mar 2015||Canaccord Genuity||Initiates Coverage on||Buy|
|Jun 2013||PiperJaffray||Initiates Coverage on||Overweight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.